On Nov 13, major Wall Street analysts update their ratings for $Mirum Pharmaceuticals (MIRM.US)$, with price targets ranging from $50 to $70.
Morgan Stanley analyst Michael Ulz maintains with a buy rating, and adjusts the target price from $59 to $60.
Citi analyst David Lebowitz maintains with a buy rating, and adjusts the target price from $64 to $68.
Baird analyst Brian Skorney maintains with a buy rating, and adjusts the target price from $44 to $50.
Stifel analyst Dae Gon Ha maintains with a buy rating, and adjusts the target price from $66 to $70.
H.C. Wainwright analyst Ed Arce maintains with a buy rating, and maintains the target price at $66.
Furthermore, according to the comprehensive report, the opinions of $Mirum Pharmaceuticals (MIRM.US)$'s main analysts recently are as follows:
Mirum Pharmaceuticals' Q3 financial results surpassed expectations largely due to robust Livmarli sales. Although some revenue was brought forward due to reimbursement dynamics, Livmarli's launch is showing promising growth and is becoming a more significant part of the company's total franchise sales.
Mirum Pharmaceuticals reported solid results that exceeded expectations, primarily due to the performance of Livmarli, prompting a revision of the FY2024 guidance to exceed the upper limit of the prior forecast.
Here are the latest investment ratings and price targets for $Mirum Pharmaceuticals (MIRM.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.